A clinical-stage biopharmaceutical firm advancing proprietary oncology and immunology candidates through late-stage clinical trials with a focus on next-generation drug mechanisms.
Investors may consider exposure if the company successfully advances its oncology pipeline to commercialization, potentially generating significant revenue from first-in-class therapies. The company's substantial marketable securities holding of $259.1M provides a runway to complete current clinical trials without immediate dilution. Potential strategic partnerships or licensing deals could provide non-dilutive funding and accelerate time-to-market for key assets.
The deepening losses with net income declining to $-285.4M in the most recent year suggest unsustainable burn rates without successful product launches. High leverage with current portion of long-term debt at $350.0M poses a severe liquidity risk if stock price declines or financing markets freeze. Lack of commercial revenue makes valuation highly speculative and dependent on binary clinical trial outcomes that carry high failure probabilities.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing proprietary medicines for oncology and immunology indications. The company serves global markets with a pipeline targeting high-need areas in cancer care and autoimmune diseases. Key products are currently in various stages of preclinical and clinical development, supported by significant R&D investments totaling approximately $259 million in the latest period.
Despite a gross profit of $172.4M, the company reported a net loss of $285.4M driven by elevated operating expenses and research and development costs of $258.8M. Cash flow from operations turned negative at $323.0M, while cash flow from investing activities showed an outflow of $290.0M primarily related to strategic acquisitions or asset purchases. The balance sheet remains stressed with a retained earnings deficit of $1.51B and total liabilities exceeding total shareholders' equity.
The biopharmaceutical industry is characterized by long development cycles, high capital intensity, and significant regulatory hurdles before products reach the market. Oncology and immunology sectors are competitive with established incumbents but offer opportunities for novel mechanisms of action in unmet medical need areas. Success depends on robust clinical data to secure FDA approval and negotiate favorable pricing strategies in a cost-conscious healthcare environment.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $23.7M | $172.4M |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $23.7M | $172.4M |
| Operating Expenses | $151.8M | $230.0M | $363.4M | $445.4M |
| Operating Income | $-151.8M | $-230.0M | $-339.7M | $-273.1M |
| R&D | $118.5M | $163.0M | $241.6M | $258.8M |
| G&A | $33.3M | $66.9M | $120.9M | $179.7M |
| Stock-Based Comp | $16.0M | $31.0M | $43.0M | $47.5M |
| Depreciation | $33.0M | $12.0M | $8.0M | $6.0M |
| Other OpEx | $0 | $0 | $826.0K | $7.0M |
| Non-Operating Income | $0 | $0 | $0 | $0 |
| Interest Expense | $3.1M | $208.0K | — | — |
| Interest Income | $5.9M | $21.2M | $26.1M | $22.7M |
| Pre-Tax Income | $-151.8M | $-230.0M | $-339.7M | $-273.1M |
| Income Tax | $-2.4M | $-20.6M | $-20.9M | $433.0K |
| Continuing Ops | $-149.3M | $-209.4M | $-318.8M | $-273.5M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-149.3M | $-209.4M | $-318.8M | $-285.4M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-149.3M | $-209.4M | $-318.8M | $-285.4M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $489.8M | $580.9M | $603.1M | $528.1M |
| Cash & Equivalents | $74.4M | $295.4M | $154.1M | $134.9M |
| Marketable Securities | $401.4M | $275.3M | $418.8M | $259.1M |
| Accounts Receivable | — | — | $7.6M | $38.0M |
| Inventory | — | — | $366.0K | $32.8M |
| Prepaid Expenses | $1.9M | $3.3M | $8.5M | $13.5M |
| Other Current Assets | $12.1M | $6.9M | $13.7M | $49.8M |
| Long-Term Assets | $7.5M | $32.0M | $121.8M | $1.6M |
| PP&E (Net) | $20.0K | $8.0K | $0 | $181.0K |
| Operating Leases | $1.0M | $1.5M | $2.0M | $1.3M |
| LT Investments | $5.5M | $29.8M | $119.5M | $0 |
| Other LT Assets | $922.0K | $680.0K | $217.0K | $102.0K |
| Total Assets | $497.2M | $612.9M | $724.8M | $529.7M |
| Current Liabilities | $29.1M | $58.1M | $103.5M | $120.1M |
| Accounts Payable | $4.3M | $10.0M | $11.6M | $16.6M |
| Current Debt | — | — | $337.9M | $350.0M |
| Current Leases | $434.0K | $1.0M | $471.0K | $470.0K |
| Other Current Liab | $24.3M | $47.1M | $-246.4M | $-246.9M |
| Long-Term Liabilities | $722.0K | $588.0K | $333.1M | $345.0M |
| LT Operating Leases | $709.0K | $578.0K | $1.6M | — |
| Other LT Liab | $13.0K | $10.0K | $331.6M | — |
| Total Liabilities | $29.8M | $58.7M | $436.7M | $465.1M |
| Shareholders' Equity | $467.4M | $554.2M | $288.1M | $64.6M |
| Retained Earnings | $-693.0M | $-902.4M | $-1.22B | $-1.51B |
| Total L&E | $497.2M | $612.9M | $724.8M | $529.7M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-149.3M | $-209.4M | $-318.8M | $-285.4M |
| Non-Cash Adjustments | $4.6M | $29.0M | $3.5M | $-168.1M |
| Working Capital Changes | $11.1M | $19.8M | $40.3M | $130.6M |
| Cash from Operations | $-133.7M | $-160.6M | $-274.9M | $-323.0M |
| Capital Expenditures | $0 | $0 | — | $187.0K |
| Cash from Investing | $-186.2M | $117.6M | $-219.8M | $290.0M |
| Cash from Financing | $172.3M | $264.1M | $353.4M | $13.7M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-147.6M | $221.1M | $-141.3M | $-19.3M |
| Beginning Cash | $222.1M | $74.5M | $295.6M | $154.3M |
| Ending Cash | $74.5M | $295.6M | $154.3M | $135.0M |
Oncology Discovery and Development", "Immunology Research and Clinical Trials", "Strategic Licensing and Partnerships
Significant net losses and negative operating cash flow indicating heavy reliance on external capital for near-term operations", "Limited commercial revenue history as the company remains in clinical development stages without current sales", "High regulatory uncertainty and potential failure risks associated with late-stage oncology drug approvals", "Substantial debt obligations including $350 million in current portion of long-term debt creating refinancing pressure
Proprietary platform technologies enabling novel mechanism of action therapies for difficult-to-treat cancers", "Strong cash position with over $134 million in liquid assets to fund development milestones", "Experienced management team with a track record of advancing complex biologic programs through FDA approval pathways
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.